Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521-546.
Buch M, Wells A, Rubbert-Roth A, et al. A comparative analysis of upadacitinib monotherapy and upadacitinib combination therapy for the treatment of rheumatoid arthritis from two phase 3 trials. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 511.
Chu AD, Chang BY. B-cell kinase inhibitors in rheumatoid arthritis. OA Arthritis. 2013;1:17.
Cohen S, Pope J, Haraoui B, et al. Efficacy and safety of tofacitinib modified-release 11 mg once daily + MTX in RA patients with an inadequate response to MTX: open-label phase results from a global phase 3b/4 MTX withdrawal study. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 1412.
Cohen S, Tuckwell K, Kunder R, et al. Efficacy and safety of fenebrutinib, a BTK inhibitor, compared to placebo in rheumatoid arthritis patients with active disease despite TNF inhibitor treatment: randomized, double blind, phase 2 study. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 929.
Combe B, Kivitz A, Tanaka Y, et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 506.
Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457-468.
Fleischmann R, Takeuchi T, Schiff M, et al. Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate. Arthritis Care Res (Hoboken). 2019. doi: 10.1002/acr.24007. [Epub ahead of print].
Gaylis N, Sikes D, Kivitz A, et al. Neurostimulation for treatment of drug refractory rheumatoid arthritis: a first-in-human study using a novel vagus nerve stimulator. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 930.
Genovese M, Smolen J, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 847.
Genovese M, Weinblatt M, Wu J, et al. Patient disease trajectories in baricitinib-2 mg-treated patients with rheumatoid arthritis and inadequate response to biologic DMARDs. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 1350.
Kremer J, Bingham C, Cappelli L, et al. Post-approval comparative safety study of tofacitinib and biologic DMARDs: five-year results from a US-based Rheumatoid Arthritis Registry. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 2372.
O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311-328. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25-36.
Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303-2311.
Takeuchi T, Tanaka Y, Rokuda M, et al. Inhibition of joint destruction in patients with rheumatoid arthritis treated with peficitinib in combination with methotrexate: a randomized, double-blind, placebo-controlled trial in Japan. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 507.
van Vollenhoven R, Takeuchi T, Pangan A, et al. Monotherapy with upadacitinib in MTX-naïve patients with rheumatoid arthritis: results at 48 weeks. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 928.
Westhovens R, Rigby W, van der Heijde D, et al G. Efficacy and safety of filgotinib for patients with rheumatoid arthritis naïve to methotrexate therapy: FINCH3 primary outcome results. Arthritis Rheumatol. 2019;71(suppl 10): Abstract 927.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Kenneth Kalunian, MD

Professor of Medicine
Division of Rheumatology, Allergy, and Immunology
University of California, San Diego School of Medicine
La Jolla, California, United States

Disclosures

Disclosure: Kenneth Kalunian, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Biogen; Bristol-Myers Squibb Company; Celgene Corporation; Equillium; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Kyowa Kirin Pharmaceutical Development, Inc.; Nektar; Pfizer Inc.; Roche; Takeda Pharmaceuticals North America, Inc.; Viela Bio
Received grants for clinical research from: Corbus; Irdosia; Resolve Therapeutics

Panelist

Iain B. McInnes, MD, PhD

Muirhead Professor of Medicine
ARUK Professor of Rheumatology
Director
Institute of Infection, Immunity, and Inflammation
College of Medical, Veterinary, and Life Sciences
Glasgow Biomedical Research Centre
University of Glasgow
Scotland, United Kingdom

Disclosures

Disclosure: Iain B. McInnes, MD, PhD has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Lilly; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc.
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc.

Yusuf Yazici, MD

Clinical Associate Professor of Medicine
New York University School of Medicine
Director
Seligman Center for Advanced Therapeutics
Behcet’s Syndrome Evaluation, Treatment and Research Center
NYU Hospital for Joint Diseases
New York, New York, United States

Disclosures

Disclosure: Yusuf Yazici, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Celgene Corporation; Sanofi
Received grants for clinical research from: Bristol-Myers Squibb Company; Celgene Corporation

Editors

Karen Badal, MD, MPH

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Karen Badal, MD, MPH, has disclosed the following relevant financial relationships:
Owns stocks, stock options or bonds from: Kallyope, Inc.

Heather Lewin, MAT

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Heather Lewin, MAT, has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CME / ABIM MOC

Rheumatoid Arthritis: Front Row Seat at the Fall Rheumatology Conference

Authors: Kenneth Kalunian, MD; Iain McInnes, MD, PhD; and Yusuf Yazici, MD
CME / ABIM MOC Released: 12/13/2019
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 12/13/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for rheumatologists, primary care physicians, and orthopaedists & orthopaedic surgeons.

The goal of this activity is to increase clinicians’ knowledge regarding the latest data in the treatment of rheumatoid arthritis.

Upon completion of this activity, participants will:

Have increased knowledge regarding
- Data on emerging therapies in RA
- Data on JAK inhibitors for RA

Disclosures

Moderator

Kenneth Kalunian, MD

Professor of Medicine
Division of Rheumatology, Allergy, and Immunology
University of California, San Diego School of Medicine
La Jolla, California, United States

Disclosures

Disclosure: Kenneth Kalunian, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Biogen; Bristol-Myers Squibb Company; Celgene Corporation; Equillium; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Kyowa Kirin Pharmaceutical Development, Inc.; Nektar; Pfizer Inc.; Roche; Takeda Pharmaceuticals North America, Inc.; Viela Bio
Received grants for clinical research from: Corbus; Irdosia; Resolve Therapeutics

Panelist

Iain B. McInnes, MD, PhD

Muirhead Professor of Medicine
ARUK Professor of Rheumatology
Director
Institute of Infection, Immunity, and Inflammation
College of Medical, Veterinary, and Life Sciences
Glasgow Biomedical Research Centre
University of Glasgow
Scotland, United Kingdom

Disclosures

Disclosure: Iain B. McInnes, MD, PhD has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Lilly; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc.
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc.

Yusuf Yazici, MD

Clinical Associate Professor of Medicine
New York University School of Medicine
Director
Seligman Center for Advanced Therapeutics
Behcet’s Syndrome Evaluation, Treatment and Research Center
NYU Hospital for Joint Diseases
New York, New York, United States

Disclosures

Disclosure: Yusuf Yazici, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Celgene Corporation; Sanofi
Received grants for clinical research from: Bristol-Myers Squibb Company; Celgene Corporation

Editors

Karen Badal, MD, MPH

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Karen Badal, MD, MPH, has disclosed the following relevant financial relationships:
Owns stocks, stock options or bonds from: Kallyope, Inc.

Heather Lewin, MAT

Senior Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Heather Lewin, MAT, has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

New Concepts and Perspectives in Rheumatoid Arthritis

From Medscape Education Rheumatology

CME / ABIM MOC

Rheumatoid Arthritis: Front Row Seat at the Fall Rheumatology Conference

Authors: Kenneth Kalunian, MD; Iain McInnes, MD, PhD; and Yusuf Yazici, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 12/13/2019

Valid for credit through: 12/13/2020

processing....

Educational Impact Challenge

The goal of this activity is to increase clinicians’ knowledge regarding the latest data in the treatment of rheumatoid arthritis.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Kenneth Kalunian, MD

Panelist

Iain B. McInnes, MD, PhD

Yusuf Yazici, MD

Editors

Karen Badal, MD, MPH

Heather Lewin, MAT

CME Reviewer

Robert Morris, PharmD

CME / ABIM MOC

Rheumatoid Arthritis: Front Row Seat at the Fall Rheumatology Conference

Target Audience and Goal Statement

Disclosures

Moderator

Kenneth Kalunian, MD

Panelist

Iain B. McInnes, MD, PhD

Yusuf Yazici, MD

Editors

Karen Badal, MD, MPH

Heather Lewin, MAT

CME Reviewer

Robert Morris, PharmD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Rheumatoid Arthritis: Front Row Seat at the Fall Rheumatology Conference

Educational Impact Challenge